[Effect of Early Application of Recombinant Human Erythropoietin on White Matter Development in Preterm Infants]

Overview

Journal Zhongguo Dang Dai Er Ke Za Zhi

Specialty Pediatrics

Date 2018 May 17

PMID 29764568

Citations 3

Authors

Shu-Shuo Yang

Fa-Lin Xu

Hui-Qing Cheng

Hao-Ran Xu

Lin Yang

Jing-Yue Xing

Lin Cheng

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate the effect of early application of recombinant human erythropoietin (rhEPO) on white matter development in preterm infants using fractional anisotropy (FA) of magnetic resonance diffusion tensor imaging (DTI).

Methods: A total of 81 preterm infants with gestational age ≤32 weeks, birth weight <1 500 g, and hospitalization within 24 hours after birth were randomly divided into rhEPO group (42 infants) and control group (39 infants). The infants in the rhEPO group were administered rhEPO, while those in the control group were given the same volume of normal saline. The preterm infants of both groups took examinations of head magnetic resonance imaging, diffusion-weighted imaging, and DTI at the corrected gestational age of 35-37 weeks. FA was calculated for the regions of interest in both groups.

Results: There was no significant difference in the incidence of intracranial hemorrhage, periventricular leukomalacia, focal cerebral white matter damage (CWMD), and extensive CWMD between rhEPO and control groups (P>0.05). Compared with the control group, the rhEPO group showed higher FA values at the posterior limb of the internal capsule, the splenium of the corpus callosum, frontal white matter, and occipital white matter (P<0.05). There was no significant difference in FA values at the parietal white matter, thalamus, lenticular nucleus, and caudate nucleus between the two groups (P>0.05).

Conclusions: Early application of rhEPO has a neuroprotective effect on white matter development in preterm infants.

Citing Articles

Erythropoietin as a Neuroprotective Drug for Newborn Infants: Ten Years after the First Use.

Perrone S, Lembo C, Gironi F, Petrolini C, Catalucci T, Corbo G Antioxidants (Basel). 2022; 11(4).

PMID: 35453337 PMC: 9031072. DOI: 10.3390/antiox11040652.

Diffusion Tensor Imaging Changes Do Not Affect Long-Term Neurodevelopment following Early Erythropoietin among Extremely Preterm Infants in the Preterm Erythropoietin Neuroprotection Trial.

Law J, Comstock B, Richards T, Traudt C, Wood T, Mayock D Brain Sci. 2021; 11(10).

PMID: 34679424 PMC: 8533828. DOI: 10.3390/brainsci11101360.

Whether Erythropoietin can be a Neuroprotective Agent against Premature Brain Injury: Cellular Mechanisms and Clinical Efficacy.

Ma X, Shi Y Curr Neuropharmacol. 2021; 20(3):611-629.

PMID: 34030616 PMC: 9608225. DOI: 10.2174/1570159X19666210524154519.

References

Ohlsson A, Aher S . Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2006; (3):CD004863. DOI: 10.1002/14651858.CD004863.pub2. View

Liu W, Shen Y, Plane J, Pleasure D, Deng W . Neuroprotective potential of erythropoietin and its derivative carbamylated erythropoietin in periventricular leukomalacia. Exp Neurol. 2011; 230(2):227-39. PMC: 3114206. DOI: 10.1016/j.expneurol.2011.04.021. View

Ling X, Tang W, Liu G, Huang L, Li B, Li X . Assessment of brain maturation in the preterm infants using diffusion tensor imaging (DTI) and enhanced T2 star weighted angiography (ESWAN). Eur J Radiol. 2013; 82(9):e476-83. DOI: 10.1016/j.ejrad.2013.04.003. View

Juul S, Pet G . Erythropoietin and Neonatal Neuroprotection. Clin Perinatol. 2015; 42(3):469-81. PMC: 4529536. DOI: 10.1016/j.clp.2015.04.004. View

Pandit A, Ball G, Edwards A, Counsell S . Diffusion magnetic resonance imaging in preterm brain injury. Neuroradiology. 2013; 55 Suppl 2:65-95. DOI: 10.1007/s00234-013-1242-x. View

Natalucci G, Latal B, Koller B, Ruegger C, Sick B, Held L . Effect of Early Prophylactic High-Dose Recombinant Human Erythropoietin in Very Preterm Infants on Neurodevelopmental Outcome at 2 Years: A Randomized Clinical Trial. JAMA. 2016; 315(19):2079-85. DOI: 10.1001/jama.2016.5504. View

Woodward L, Anderson P, Austin N, Howard K, Inder T . Neonatal MRI to predict neurodevelopmental outcomes in preterm infants. N Engl J Med. 2006; 355(7):685-94. DOI: 10.1056/NEJMoa053792. View

Arfanakis K, Haughton V, Carew J, Rogers B, Dempsey R, Meyerand M . Diffusion tensor MR imaging in diffuse axonal injury. AJNR Am J Neuroradiol. 2002; 23(5):794-802. PMC: 7974716. View

Jobe A, Bancalari E . Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001; 163(7):1723-9. DOI: 10.1164/ajrccm.163.7.2011060. View

10.

Juul S . Recombinant erythropoietin as a neuroprotective treatment: in vitro and in vivo models. Clin Perinatol. 2004; 31(1):129-42. DOI: 10.1016/j.clp.2004.03.004. View

11.

Zhao X, Chen Y, Qiu G, Xiao M, Zhong N . Reducing preterm births in China. Lancet. 2012; 380(9848):1144-5. DOI: 10.1016/S0140-6736(12)61661-4. View

12.

Lawn J, Blencowe H, Oza S, You D, Lee A, Waiswa P . Every Newborn: progress, priorities, and potential beyond survival. Lancet. 2014; 384(9938):189-205. DOI: 10.1016/S0140-6736(14)60496-7. View

13.

Li B, Liu G, Ling X, Chen H, Luo X . [Evaluation of white matter myelination in preterm infants using DTI and MRI]. Zhongguo Dang Dai Er Ke Za Zhi. 2016; 18(6):476-81. PMC: 7389077. View

14.

Chen D, Mao J, Li J, Liu L, Zhang Y . [Clinical and imaging features in late preterm infants with cerebral white matter damage]. Zhongguo Dang Dai Er Ke Za Zhi. 2010; 12(5):321-6. View

15.

Song J, Sun H, Xu F, Kang W, Gao L, Guo J . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Ann Neurol. 2016; 80(1):24-34. PMC: 5084793. DOI: 10.1002/ana.24677. View

16.

van der Kooij M, Groenendaal F, Kavelaars A, Heijnen C, van Bel F . Neuroprotective properties and mechanisms of erythropoietin in in vitro and in vivo experimental models for hypoxia/ischemia. Brain Res Rev. 2008; 59(1):22-33. DOI: 10.1016/j.brainresrev.2008.04.007. View

17.

Juul S . Neuroprotective role of erythropoietin in neonates. J Matern Fetal Neonatal Med. 2012; 25 Suppl 4:105-7. DOI: 10.3109/14767058.2012.715025. View

18.

Back S, Luo N, Mallinson R, OMalley J, Wallen L, Frei B . Selective vulnerability of preterm white matter to oxidative damage defined by F2-isoprostanes. Ann Neurol. 2005; 58(1):108-20. DOI: 10.1002/ana.20530. View

19.

Robinson S, Li Q, Dechant A, Cohen M . Neonatal loss of gamma-aminobutyric acid pathway expression after human perinatal brain injury. J Neurosurg. 2006; 104(6 Suppl):396-408. PMC: 1762128. DOI: 10.3171/ped.2006.104.6.396. View

20.

Liu X, Mao J, Li J, Chen D, Qi Y, Gao J . [MRI-DTI evaluation of punctate cerebral white matter damage in preterm infants]. Zhongguo Dang Dai Er Ke Za Zhi. 2015; 17(6):554-9. View